Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys

References

• BARR, W. H. and RIEGELMAN, S., 1970, Intestinal drug absorption and metabolism. I. Comparison of methods and models to studying physiological factors of in vitro and in vivo intestinal absorption. Journal Pharmaceutical Sciences, 59, 154–163.
   PubMed Web of Science ®Google Scholar
• CHEN, I.-W., VASTAG, K. J and LIN, J. H., 1995, High-performance liquid chromatographic determination of a potent and selective HIV protease inhibitor (L-735,524) in rat, dog and monkey plasma. Journal of Chromatography, 672, 111–117.
   Google Scholar
• DEUTSCH, P. J., YEH, K. C., Ju, W. D., STONE, J. A., ZHONG, L., ROSE, M. J., KENNY, E., MICHIELS, N., LENS, S., ZUCKERMAN, J. and GUILLAUME, M., 2000, Pharmacokinetics and tolerability of MK-944a, a combination of a new HIV protease inhibitor with indinavir, in phase I studies. In Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections, p. 506.
   Google Scholar
• DORSEY, B. D, MCDONOUGH, C., MCDANIEL, S. L., LEVIN, R. B., NEWTON, C. L., HOMAN, J. M., DARKE, P. L., ZUGAY-MURPHY, J. A., EMINI, E. A., SCHLEIF, W. A., OLSEN, D. B., STAHLHUT, M. W., RUTKOWSKI, C. A., Kuo L. C., LIN, J. H., CHEN, I. W., MICHELSON, S. R., HOLLOWAY, M. K., Hu, J. R. and VACCA, J. P., 2000, Identification of MK-944a: a second clinical candidate from hydroxylaminepentanamide isostere series of HIV protease inhibitors. Journal of Medicinal Chemistry, 43, 3386–3399.
   Google Scholar
• GIBALDI, M. and PERRIER, D., 1982, Pharmacokinetics, 2nd edn (New York: Marcel Dekker).
   Google Scholar
• JONES, T. E., 1997, The use of other drugs to allow a lower dosage of cyclosporin to be used: therapeutic and pharmacoeconomic considerations. Clinical Pharmacokinetics, 32, 357–637.
   PubMed Web of Science ®Google Scholar
• KEOGH, A., SPRATT, P., MCCOSKER, C., MACDONALD, P., MUNDAY, J. and KAAN, A., 1995, Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. New England Journal of Medicine, 333, 628–633.
   PubMed Web of Science ®Google Scholar
• KOUDRIAKOVA, T., IATSIMIRSKAIA, E., UTKIN, I., GANGL, E., VOUROS, P., STOROZHUK, E., ORZA, D., MARININA, J. and GERBER, N., 1998, Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metabolism and Disposition, 26, 552–561.
   PubMed Web of Science ®Google Scholar
• KUMAR, G. N., DYKSTRA, J., ROBERTS, E. M., JAVANTI, V. K., HICKMAN, E., UCHIC, J., TAO, Y., SURBER, B., THOMAS, S. and GRANNEMAN, G. R., 1999, Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug—drug interaction. Drug Metabolism and Disposition, 27, 902–908.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., 1995, Species similarities and differences in pharmacokinetics. Drug Metabolism and Disposition, 23, 1008–1021.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., 1996, In vitro and in vivo drug interaction with indinavir. Paper presented at the Symposium on Recent Advances in Drug—Drug Interaction, 10–11 December, Washington, DC.
   Google Scholar
• LIN, J. H., 1997, Human immunodeficiency virus protease inhibitors: from drug design to clinical studies. Advanced Drug Delivery Reviews, 27, 215–233.
   PubMedGoogle Scholar
• LIN, J. H., 2000, Sense and nonsense in the prediction of drug—drug interactions. Current Drug Metabolism, 1, 305–331.
   PubMed Web of Science ®Google Scholar
• LIN, J. H., CHIBA, M., BALANI, S. K., CHEN, I. W., KWEI, G. Y. S., VASTAG, K. J. and NISHIME, J. A., 1996, Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metabolism and Disposition, 24, 1111–1120.
   Google Scholar
• LIN, J. H. and Lu, A. Y. H., 1998, Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics, 35, 361–390.
   PubMed Web of Science ®Google Scholar
• MEI, Q., TANG, C., ASSANG, C., LIN, Y., SLAUGHTER, D., RODRIGUES, A. D., BAILLIE, T. A., RUSHMORE, T. H. and Suou, M., 1999, Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism. Journal of Pharmacology and Experimental Therapeutics, 291, 749–759.
   PubMed Web of Science ®Google Scholar
• MEI, Q., TANG, C. Y., LIN, Y., RUSHMORE, T. H. and Suou, M., 2002, Inhibition kinetics of monoclonal antibodies against cytochromes P450. Drug Metabolism and Disposition, 30, 701–708.
   PubMedGoogle Scholar
• ROCCII, JR, M. L. and JusKo, W. J., 1983, Lagran program for area and moments in pharmaceutical analysis. Computer Programs in Biomedicine, 16, 203–216.
   Google Scholar
• SHAM, H. L., KEMPE, D. J., MOLLA, A., MARSH, K. C., KUMAR, D. N., CHEN, C. M., KATI, W., STEWART, K., LAL, R., Hsu, A., BETEBENNER, D., KORNEYEVA, M., VASAVANONDA, S., MCDONALD, E., SALDIVAR, A., WIDEBURG, N., CHEN, X., Niu, P., PARK, C., JAYANTI, V., GRABOWSKI, B., GRANNEMAN, G. R., SUN, E., JAPOUR, A. J., PLATTNER, J. and NORBECK, D., 1998, ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents and Chemotherapy, 42, 3218–3234.
   PubMed Web of Science ®Google Scholar
• TSUNODA, S. M., VELEZ, R. L., VON MOLTKE, L. L. and GREENBLATT, D. J., 1999, Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clinical Pharmacology and Therapeutics, 66,461–471.
   PubMed Web of Science ®Google Scholar
• VACCA, J. P. and CONDRAA, J. H., 1997, Clinically effective HIV-1 protease inhibitors. Drug Discovery Today, 2, 261–272.
   Web of Science ®Google Scholar
• WILKINSON, G. R., 1987, Clearance approaches in pharmacology. Pharmacology Reviews, 39, 1-47. YEE, G. C. and McGuiRE, T. R., 1990, Pharmacokinetic drug interaction with cyclosporin: I. Journal of Pharmacology and Experimental Therapeutics, 19, 312–332.
   Google Scholar